Sign in or create an account to add this stock to your watchlist.
About MorphoSys (ETR:MOR)
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase III clinical trial for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL antibody directed against CD38, which is in Phase II trial for the treatment of multiple myeloma and other cancers. The company's product pipeline also comprises MOR103/GSK3196165, a human HuCAL antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trial for treating rheumatoid arthritis and inflammatory hand osteoarthritis. In addition, its product pipeline includes MOR106, a human monoclonal antibody directed against IL-17C, which is in Phase I clinical trial for the treatment of atopic dermatitis; and MOR107 that is in preclinical investigation with a focus on oncology indications. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao. The company was founded in 1992 and is headquartered in Planegg, Germany.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolETR:MOR
CUSIPN/A
Phone+49-89-899270
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-159.62%
Return on Equity-25.28%
Return on Assets-22.11%
Miscellaneous
EmployeesN/A
Outstanding Shares29,010,000
MorphoSys (ETR:MOR) Frequently Asked Questions
What is MorphoSys' stock symbol?
MorphoSys trades on the ETR under the ticker symbol "MOR."
What price target have analysts set for MOR?
10 equities research analysts have issued 12 month target prices for MorphoSys' stock. Their forecasts range from €58.00 to €103.00. On average, they anticipate MorphoSys' stock price to reach €89.10 in the next year. View Analyst Ratings for MorphoSys.
Who are some of MorphoSys' key competitors?
Some companies that are related to MorphoSys include Ablynx (ABLX), MorphoSys (MPSYY), BTG (BTG), Abcam (ABC), Sosei Group (SOLTF), Sirtex Medical (SRX), Genus (GNS), Biotest (BIO), ProMetic Life Sciences (PLI), Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Mesoblast (MEOBF), Starpharma (SPL) and MediGene (MDG1).
Who are MorphoSys' key executives?
MorphoSys' management team includes the folowing people:
- Dr. Simon E. Moroney Ph.D., Chairman of Management Board and Chief Exec. Officer
- Mr. Jens H. Holstein, Chief Financial Officer and Member of Management Board
- Dr. Malte Peters, Chief Devel. Officer and Member of Management Board (Age 56)
- Dr. Markus Enzelberger, Chief Scientific Officer
- Dr. Marlies Sproll, Special Adviser to the Chief Exec. Officer (Age 60)
Has MorphoSys been receiving favorable news coverage?
News articles about MOR stock have trended very positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MorphoSys earned a media sentiment score of 0.65 on Accern's scale. They also assigned headlines about the company an impact score of 48.61 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
What is MorphoSys' stock price today?
One share of MOR stock can currently be purchased for approximately €91.75.
How big of a company is MorphoSys?
MorphoSys has a market capitalization of $2.49 billion.
How can I contact MorphoSys?
MorphoSys' mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-899270.
MarketBeat Community Rating for MorphoSys (MOR)
MarketBeat's community ratings are surveys of what our community members think about MorphoSys and other stocks. Vote "Outperform" if you believe MOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
MorphoSys (ETR:MOR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for MorphoSys in the last 12 months. Their average twelve-month price target is €89.10The high price target for MOR is €103.00 and the low price target for MOR is €58.00. There are currently 2 sell ratings, 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Hold | Buy |
| Consensus Rating Score: | 2.50 | 2.50 | 2.44 | 2.86 |
| Ratings Breakdown: | 2 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | €89.10 | €86.50 | €81.33 | €84.43 |
MorphoSys (ETR:MOR) Consensus Price Target History
MorphoSys (ETR:MOR) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
MorphoSys (ETR:MOR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
MorphoSys (ETR MOR) Insider Trading and Institutional Ownership History
MorphoSys (ETR MOR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
MorphoSys (ETR MOR) News Headlines
| Source: |
|
MorphoSys (ETR:MOR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
MorphoSys (ETR MOR) Stock Chart for Friday, May, 25, 2018
Loading chart…
